OS Therapies Incorporated (OSTX) News

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer...

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

Patent Term Adjustment will provide market exclusivity in the United States into 2040 for all therapeutic indications OS Therapies, Inc...

Form 4 - Statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer...

Form EFFECT - Notice of Effectiveness

Form PRE 14A - Other preliminary proxy statements

Form 3 - Initial statement of beneficial ownership of securities

OS Therapies Provides Corporate Update

Strong cash position relative to monthly burn and cash needs into mid-2026 Significant regulatory milestones upcoming in OST-HER2 osteosarcoma...

Form S-1 - General form for registration of securities under the Securities Act of 1933

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline

Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations...